Definium Therapeutics (NASDAQ:DFTX) CEO Sells 31,550 Shares of Company Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 31,550 shares of the firm’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the sale, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at $80,932,701.30. The trade was a 1.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Barrow also recently made the following trade(s):

• On Thursday, September 3rd, Robert Barrow sold 19,023 shares of Definium Therapeutics stock. The stock was sold at an average price of $37.94, for a total transaction of $721,732.62.

Definium Therapeutics Stock Performance

NASDAQ:DFTX traded down $0.20 during trading hours on Tuesday, reaching $38.21. 1,967,182 shares of the stock were exchanged, compared to its average volume of 2,245,960. The stock has a market capitalization of $5.13 billion, a P/E ratio of -11.14 and a beta of 2.23. The firm has a 50 day simple moving average of $41.37 and a 200-day simple moving average of $32.06. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics, Inc. has a 52 week low of $10.46 and a 52 week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts forecast that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DFTX shares. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. Robert W. Baird increased their price target on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. Oppenheimer reissued an “outperform” rating and issued a $75.00 price target on shares of Definium Therapeutics in a report on Monday, September 14th. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Finally, Bank of America assumed coverage on Definium Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $64.88.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP acquired a new stake in shares of Definium Therapeutics in the 2nd quarter worth approximately $138,755,000. Avoro Capital Advisors LLC acquired a new position in shares of Definium Therapeutics during the fourth quarter valued at approximately $66,950,000. Bank of New York Mellon Corp raised its holdings in Definium Therapeutics by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after purchasing an additional 24,349 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in Definium Therapeutics in the second quarter worth approximately $6,992,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in Definium Therapeutics in the second quarter worth approximately $1,592,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.